Article Synopsis
- The fast development of biological imaging technology and its various uses has made it hard to create a universally accepted data format.
- The authors suggest enhancing existing open formats like OME-TIFF and HDF5 with the new Zarr file format to support most bioimaging needs.
- Using a standard metadata format across these file types can improve the ability to find, access, share, and reuse bioimaging data effectively.
Video Abstracts
Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The rapid pace of innovation in biological imaging and the diversity of its applications have prevented the establishment of a community-agreed standardized data format. We propose that complementing established open formats such as OME-TIFF and HDF5 with a next-generation file format such as Zarr will satisfy the majority of use cases in bioimaging. Critically, a common metadata format used in all these vessels can deliver truly findable, accessible, interoperable and reusable bioimaging data.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648559 | PMC |
| http://dx.doi.org/10.1038/s41592-021-01326-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RabbitBAM: Accelerating BAM File Manipulation on Multi-Core Platforms.
IEEE Trans Comput Biol Bioinform
July 2025
With the continuous advancement of sequencing technology, the scale of biological data has rapidly increased. BAM format, widely used for storing aligned sequence data, is very popular due to its ease of use and good compression ratio. However, existing BAM-format file I/O libraries often fail to fully leverage the computational power of modern multi-core platforms, resulting in low CPU utilization.
View Article and Find Full Text PDFHybrid intelligence systems for reliable automation: advancing knowledge work and autonomous operations with scalable AI architectures.
Front Robot AI
July 2025
MSBAI, Los Angeles, CA, United States.
Introduction: Mission-critical automation demands decision-making that is explainable, adaptive, and scalable-attributes elusive to purely symbolic or data-driven approaches. We introduce a hybrid intelligence (H-I) system that fuses symbolic reasoning with advanced machine learning a hierarchical architecture, inspired by cognitive frameworks like Global Workspace Theory (Baars, A Cognitive Theory of Consciousness, 1988).
Methods: This architecture operates across three levels to achieve autonomous, end-to-end workflows: Navigation: Using Vision Transformers, and graph-based neural networks, the system navigates file systems, databases, and software interfaces with precision.
MitSorter: a standalone tool for accurate discrimination of mtDNA and NuMT ONT reads based on differential methylation.
Bioinform Adv
July 2025
Department of Biosciences, Biotechnology and Environment, University of Bari Aldo Moro, Bari 70125, Italy.
Motivation: The accurate differentiation between mitochondrial DNA (mtDNA) and nuclear mitochondrial DNA segments (NuMTs) is a critical challenge in studies involving mitochondrial disorders. Mapping the mtDNA mutation spectrum and quantifying heteroplasmy are complex tasks when using next-generation sequencing methods, mostly due to NuMTs contamination in data analysis.
Results: Here, we present a novel, easy-to-use standalone command-line tool designed to reliably discriminate long reads originated by either mtDNA or NuMTs and generated by Oxford Nanopore Technologies (ONT) sequencing based on the known lack of CpG methylation in human mtDNA.
Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO).
BMC Cancer
July 2025
Department of Surgery, Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, 14000, France.
Background: The identification of homologous recombination deficient (HRD) tumor is now a crucial step for the therapeutic management of ovarian cancer. The HRD tumors are both sensitive to olaparib maintenance treatment and to platinum-based chemotherapy. Despite the large amount of HRD tests currently available, only a few HRD tests were prospectively validated on a clinical cohort of patients with ovarian cancer.
View Article and Find Full Text PDFEvaluation of Bridge Capture technology for mutation profiling in liquid biopsies of metastatic colorectal cancer patients.
Sci Rep
July 2025
Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths, often presenting at an advanced stage with significant molecular heterogeneity. This is the first study to evaluate the performance of a novel next-generation sequencing (NGS)-based Bridge Capture technology for mutation profiling and minimal residual disease detection in circulating tumor (ct)DNA from metastatic colorectal cancer (mCRC) patients. Its performance was compared to those of droplet digital PCR (ddPCR), Ion AmpliSeq Cancer Hotspot Panel v2, and Idylla ctKRAS Mutation Assay.
View Article and Find Full Text PDF